Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India | PLOS ONE
Frontiers | Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to | SpringerLink
Cells | Free Full-Text | Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis
Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection
Evolution of efficacious pangenotypic hepatitis C virus therapies - Ashraf - 2019 - Medicinal Research Reviews - Wiley Online Library
New perspectives for preventing hepatitis C virus liver graft infection - The Lancet Infectious Diseases
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update | SpringerLink
Sofosbuvir-Velpatasvir Epclusa - Treatment - Hepatitis C Online
Viruses | Free Full-Text | Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir | Scientific Reports
Epclusa (sofosbuvir + velpatasvir)
Sofosbuvir/velpatasvir: A promising combination
Sofosbuvir, a Significant Paradigm Change in HCV Treatment
Sofosbuvir - Wikipedia
Amino Acid and Peptide‐Based Antiviral Agents - Skwarecki - 2021 - ChemMedChem - Wiley Online Library
Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents: Challenges in Developing Countries - ScienceDirect
Plant Uptake and Metabolism of 2,4-Dibromophenol in Carrot: In Vitro Enzymatic Direct Conjugation | Journal of Agricultural and Food Chemistry
Sofosbuvir/Velpatasvir (Epclusa®) Drug Interactions A Quick Guide for Clinicians – February 2019
Frontiers | Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects
Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant | ACS Omega
PathWhiz
Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
Antivirals for Hepatitis C | Concise Medical Knowledge
